| Identification | Back Directory | [Name]
BNC105 | [CAS]
945771-74-4 | [Synonyms]
BNC105
CS-2127
2-methyl-7-hydroxy-6-methoxy-3-(3,4,5-trimethoxybenzoyl)benzo[b]furan
Methanone, (7-hydroxy-6-methoxy-2-methyl-3-benzofuranyl)(3,4,5-trimethoxyphenyl)- | [Molecular Formula]
C20H20O7 | [MDL Number]
MFCD22628798 | [MOL File]
945771-74-4.mol | [Molecular Weight]
372.37 |
| Chemical Properties | Back Directory | [Melting point ]
156-158 °C(Solv: methanol (67-56-1)) | [Boiling point ]
529.3±50.0 °C(Predicted) | [density ]
1.261±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO:25.0(Max Conc. mg/mL);67.14(Max Conc. mM) | [form ]
A solid | [pka]
6.60±0.50(Predicted) | [color ]
Light yellow to yellow |
| Hazard Information | Back Directory | [Uses]
BNC105 is a tubulin polymerization inhibitor with potent antiproliferative and tumor vascular disrupting properties. | [References]
[1] Flynn BL, et al. Discovery of 7-hydroxy-6-methoxy-2-methyl-3-(3,4,5-trimethoxybenzoyl)benzo[b]furan (BNC105), a tubulin polymerization inhibitor with potent antiproliferative and tumor vascular disrupting properties. J Med Chem. 2011 Sep 8;54(17):6014-27. DOI:10.1021/jm200454y
[2] Kremmidiotis G, et al. BNC105: a novel tubulin polymerization inhibitor that selectively disrupts tumor vasculature and displays single-agent antitumor efficacy. Mol Cancer Ther. 2010 Jun;9(6):1562-73. DOI:10.1158/1535-7163.MCT-09-0815
[3] Inglis DJ, et al. The vascular disrupting agent BNC105 potentiates the efficacy of VEGF and mTOR inhibitors in renal and breast cancer. Cancer Biol Ther. 2014;15(11):1552-60. DOI:10.4161/15384047.2014.956605 |
|
| Company Name: |
SPIRO PHARMA
|
| Telephone: |
|
| Website: |
www.spiropharma.com.cn |
| Company Name: |
Twochem Co.Ltd.
|
| Telephone: |
021-58111628 15800915896 |
| Website: |
cn.twochem.com |
|